Fujifilm Diosynth Biotechnologies announced a 10-year manufacturing supply agreement, valued at over $3 billion, with Regeneron Pharmaceuticals to provide U.S.-based production of its biologic medicines.

Per the terms of the agreement, Fujifilm Diosynth Biotechnologies will provide U.S.-based manufacturing for Regeneron over the next 10 years through current and planned expansions at its new large-scale biopharmaceutical manufacturing facility in Holly Springs, NC, when the site begins operations later this year.

“The Holly Springs site is part of our kojoX interconnected manufacturing network, which provides a first-of-its-kind modular approach with standardized equipment, processes, and procedures across our sites around the globe to help ensure supply chain security and seamless tech transfers,” said Lars Petersen, president and chief executive officer, Fujifilm Diosynth Biotechnologies.

Toshihisa Iida, director, corporate vice president, general manager of Life Sciences Strategy Headquarters and Bio-CDMO Division, Fujifilm Corporation, Japan, said, “Fujifilm Diosynth Biotechnologies will be bringing additional capacity online in 2025, 2026 and beyond as it completes the current $7 billion of expansion projects underway in both Europe and United States.”